Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MDxHealth (MDXH) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for MDxHealth (MDXH) over the last 6 years, with Q3 2025 value amounting to $46.8 million.

  • MDxHealth's Cash & Equivalents fell 502.11% to $46.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.8 million, marking a year-over-year decrease of 502.11%. This contributed to the annual value of $46.8 million for FY2024, which is 10910.63% up from last year.
  • Per MDxHealth's latest filing, its Cash & Equivalents stood at $46.8 million for Q3 2025, which was down 502.11% from $262.0 billion recorded in Q2 2025.
  • MDxHealth's Cash & Equivalents' 5-year high stood at $262.0 billion during Q2 2025, with a 5-year trough of $14.5 million in Q1 2024.
  • For the 5-year period, MDxHealth's Cash & Equivalents averaged around $16.4 billion, with its median value being $46.8 million (2024).
  • As far as peak fluctuations go, MDxHealth's Cash & Equivalents tumbled by 7349.82% in 2022, and later surged by 122722383.81% in 2025.
  • MDxHealth's Cash & Equivalents (Quarter) stood at $58.5 million in 2021, then plummeted by 73.5% to $15.5 million in 2022, then surged by 44.36% to $22.4 million in 2023, then soared by 109.11% to $46.8 million in 2024, then changed by 0.0% to $46.8 million in 2025.
  • Its Cash & Equivalents was $46.8 million in Q3 2025, compared to $262.0 billion in Q2 2025 and $65.7 million in Q1 2025.